Cesca Therapeutics Names CFO

Rancho Cordova, Calif.-based Cesca Therapeutics Inc. has made it official: Mike Bruch, appointed interim chief financial officer in May, has been placed in the role permanently.

Prior to his appointment, he served as controller since joining the company in 2003. In this role he was responsible for the company’s accounting and internal control functions. He also played a key role in integrating TotipotentRX after the 2014 merger between the two companies. Bruch has over 25 years of experience in various financial and managerial roles at a number of world-class companies, including General Electric and Dada Micro Scan (now Siemens Healthcare). He is a certified public accountant and graduated with honors from California State University, Sacramento, with a bachelor of science degree in business administration.

“I am delighted that Mike has accepted the position of chief financial officer. He has done an outstanding job as Interim CFO, reinforcing our belief that he is the right person to lead the company’s finance function as we continue our transformation into a fully integrated regenerative medicine company.”

Cesca Therapeutics makes autologous cell-based therapeutics for use in regenerative medicine.